STAT+: Pharmalittle: We’re reading about FDA hiring delays, a new Bavarian Nordic CEO, and more

Good morning, and welcome to the middle of the week. The day is almost over, but there are still a few more hours to go before the weekend arrives. Take advantage of this time and keep pushing forward with your goals. Today, we suggest a refreshing pomegranate green tea to help stimulate your mind as you read through the latest news headlines.

The U.S. Food and Drug Administration (FDA) is opening applications for a pilot program aimed at reducing the time it takes for drug manufacturers to begin testing their products on humans. This initiative is part of Operation TrialBlazer, a project launched by the U.S. Department of Health and Human Services, which aims to speed up FDA drug approval timelines and help the United States compete with biotechnology industries in countries like China and Australia.

The pilot program seeks to establish a network of qualified research institutions that will collaborate with companies to develop and review Investigational New Drug application packages. In Montana, investors from the libertarian sector of the biotech industry have made it possible for individuals to gain widespread access to experimental drugs. Last year, they played a crucial role in drafting a state law that expanded access to drugs that have not yet been approved by regulators for safety and effectiveness.

In Montana, a privately-managed board is now responsible for deciding which treatments to offer, leading to concerns about potential conflicts of interest and whether patients will receive value for their money. The company handling this process works with biotech firms in a region off the coast of Honduras, where there is no drug regulator. Startup biotech firms are hopeful that Montana will serve as a shortcut to bypass the lengthy and costly FDA drug development process.